Approval · Notice of Compliance 23436 · 2020
ENTYVIO: Notice of Compliance 23436
Issued April 7, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23436
- Date
- April 7, 2020
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New subcutaneous presentation for use in patients with ulcerative colitis. additional manufacturing site
Products in this notice
Medicinal ingredients
- VEDOLIZUMAB 108 MG per SYR
- VEDOLIZUMAB 108 MG per PEN